Zicronapine

Zicronapine

Systematic (IUPAC) name
4-[(1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl]-1,2,2-trimethylpiperazine
Identifiers
CAS Number	170381-16-5
PubChem	CID 11465618
DrugBank	DB05828
ChemSpider	9640456
UNII	QZV11V7G6A
KEGG	D10329
Chemical data
Formula	C22H27ClN2
Molar mass	354.9 g/mol
SMILES Clc1ccc4c(c1)[C@H](N2CC(N(C)CC2)(C)C)C[C@H]4c3ccccc3
InChI InChI=1S/C22H27ClN2/c1-22(2)15-25(12-11-24(22)3)21-14-19(16-7-5-4-6-8-16)18-10-9-17(23)13-20(18)21/h4-10,13,19,21H,11-12,14-15H2,1-3H3/t19-,21+/m0/s1 Key:BYPMJBXPNZMNQD-PZJWPPBQSA-N

Zicronapine (zye-KRON-a-peen, previously known as Lu 31-130) is an atypical antipsychotic medication formerly under development by H. Lundbeck A/S. In phase II studies zicronapine showed statistically significant separation from placebo and convincing efficacy and safety data when compared to olanzapine.^[1]

Zicronapine exhibits monoaminergic activity and has a multi-receptorial profile. In vitro and in vivo it has shown potent antagonistic effects at dopamine D₁, D₂ and serotonin 5HT_2A receptors.^[2]

In 2014 Lundbeck removed zicronapine from its development portfolio in favor of pursuing the more promising medicine Lu AF35700.^[3]

References

1. "The clinical phase III programme commenced on zicronapine". January 20, 2011. Retrieved 6 February 2014.
2. "Zicronapine shows significant positive data in clinical phase II in the treatment of patients with schizophrenia - planning for continued clinical work". December 18, 2009. Retrieved 6 February 2014.
3. "Performance in 2014 positions Lundbeck well for 2015 and beyond" (PDF). February 5, 2015. Retrieved 18 June 2015.